Alastair Buchan (born 16 October 1955) is a British neurologist and researcher in stroke medicine. His main research interest is how to make neuroprotection a reality in the clinic. From October 2008 until January 2017, he served as the Dean of Medicine and the Head of the Medical Sciences Division, University of Oxford. [1] He currently holds the Chair of Stroke Research at the University of Oxford.
Buchan was educated at Repton School in Derbyshire and graduated in 1980 from his medical studies at the University of Cambridge, University of Oxford and Harvard University.
He undertook his post-graduate medical training with Sir David Weatherall in Oxford and completed his neurological training in North America, with Henry J. M. Barnett in London, Ontario and in stroke with Fred Plum in New York.
Buchan held staff positions as a consultant neurologist in London and Ottawa before becoming the Heart and Stroke Foundation Professor in Stroke Research in Calgary, Alberta in 1995.
During ten years in Calgary, Buchan built up a team which established a fully comprehensive regional Stroke Programme and led large multi-centre studies CASES, ASPECTS and FASTER. When he returned to Oxford in 2005, he left Calgary with an Acute Stroke Imaging Centre, an Experimental Imaging Centre and the Clinical Stroke Programme, which facilitate translation of the experimental research work in the laboratory to the clinical setting. For his services, the University of Calgary awarded Buchan an honorary Degrees of Laws (LLD) in May 2009.
His early work at Oxford included obtaining funding from the MRC, the Leducq Foundation and the Dunhill Foundation to set up an Acute Stroke Programme in collaboration with Peter Jezzard and Peter Rothwell. He was the Translational Research Director for the UK Stroke Research Network. He also led the Oxford University bid for a Wellcome Clinical Research facility and successfully obtained funding for the new Acute Vascular Imaging Centre (AVIC).
Buchan was initially elected to the Chair of Clinical Geratology [2] but now holds the Chair of Stroke Research, named for George Pickering, at the University of Oxford.
In 2006, Buchan was appointed Director for the National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Centre, [3] one of the five comprehensive centres. At the same time, he was charged with the task of heading the John Radcliffe Hospital Division of the Nuffield Department of Medicine. [4] He established and chaired the cabinet of the UK Biomedical Research Directors for the other five centres in the country.
Appointed Dean and Head of the Medical Sciences Division in 2007, he was instrumental in establishing a number of new departments in the university, including the Nuffield Department of Clinical Neurosciences, the Department of Oncology, the Nuffield Department of Population Health, the Nuffield Department of Primary Health and the Radcliffe Department of Medicine, as well as the Oxford University Hospitals NHS Trust in November 2011. [5]
In his previous position as Pro-Vice-Chancellor and Head of Brexit Strategy [6] he brokered partnerships with the Universities and hospitals in Berlin to establish the Oxford-Berlin Research Partnership which includes a centre for Oxford in Berlin. [7] [8]
In April 2007 he was made a Fellow of the Academy of Medical Sciences (FMedSci). [9]
Angela Vincent is a British neuroscientist who is emeritus professor at the University of Oxford and a Fellow of Somerville College, Oxford.
The Nuffield Orthopaedic Centre (NOC) is an orthopaedic hospital, with strong affiliations to the University of Oxford. It provides routine and specialist orthopaedic surgery, plastic surgery and rheumatology services to the people of Oxfordshire. Specialist services, such as the treatment of osteomyelitis and bone tumours, and the rehabilitation of those with limb amputation, congenital deficiency and neurological disabilities, are provided for patients from across the UK and abroad. It is managed by the Oxford University Hospitals NHS Foundation Trust.
Sir David Keith Peters is a retired Welsh physician and academic. He was Regius Professor of Physic at the University of Cambridge from 1987 to 2005, where he was also head of the School of Clinical Medicine.
The Clinical Trial Service Unit (CTSU) is a medical research institute within the Nuffield Department of Population Health at Oxford University. It primarily conducts large scale clinical trials and epidemiological studies of chronic diseases, especially cancer and vascular conditions. It is located in the Richard Doll Building (RDB) on the Old Road Campus, in Headington, Oxford, England.
John Andrew Todd is a British geneticist who is Professor of Precision Medicine at the University of Oxford, director of the Wellcome Center for Human Genetics and the JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, in addition to Jeffrey Cheah Fellow in Medicine at Brasenose College. He works in collaboration with David Clayton and Linda Wicker to examine the molecular basis of type 1 diabetes.
The Wellcome Centre for Human Genetics is a human genetics research centre of the Nuffield Department of Medicine in the Medical Sciences Division, University of Oxford, funded by the Wellcome Trust among others.
Andrew Jonathan Carr, FMedSci is a British surgeon and has been the sixth Nuffield Professor of Orthopaedics and head of the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences at the University of Oxford since 2001.
Stephen William MacMahon is a British-Australian academic medical researcher, healthcare entrepreneur and founder of The George Institute for Global Health. He holds professorial academic appointments in medicine at UNSW Sydney and Imperial College London.
The various academic faculties, departments, and institutes of the University of Oxford are organised into four divisions, each with its own Head and elected board. They are the Humanities Division; the Social Sciences Division; the Mathematical, Physical and Life Sciences Division; and the Medical Sciences Division.
Oxford University School of Medicine & Biomedical Sciences is the medical school of the University of Oxford in the city of Oxford, England. It is a component of the Medical Sciences Division, and teaching is carried out in its various constituent departments.
Robert E. MacLaren FMedSci FRCOphth FRCS FACS VR is a British ophthalmologist who has led pioneering work in the treatment of blindness caused by diseases of the retina. He is Professor of Ophthalmology at the University of Oxford and Honorary Professor of Ophthalmology at the UCL Institute of Ophthalmology. He is a Consultant Ophthalmologist at the Oxford Eye Hospital. He is also an Honorary Consultant Vitreo-retinal Surgeon at the Moorfields Eye Hospital. MacLaren is an NIHR Senior Investigator, or lead researcher, for the speciality of Ophthalmology. In addition, he is a member of the research committee of Euretina: the European Society of Retina specialists, Fellow of Merton College, in Oxford and a Fellow of the Higher Education Academy.
Edith Yvonne Jones is a British molecular biologist who is director of the Cancer Research UK Receptor Structure Research Group at the University of Oxford and a Fellow of Jesus College, Oxford. She is widely known for her research on the molecular biology of cell surface receptors and signalling complexes.
Sir Andrew James McMichael, is an immunologist, Professor of Molecular Medicine, and previously Director of the Weatherall Institute of Molecular Medicine at the University of Oxford. He is particularly known for his work on T cell responses to viral infections such as influenza and HIV.
Sarah Elizabeth Lamb is the Pro-Vice-Chancellor and Executive Dean of the Faculty of Health and Life Sciences at the University of Exeter, and the Mireille Gillings Professor for Health Innovation. She is also an Honorary Departmental Professor at the Nuffield Department of Medicine, University of Oxford and was the Foundation Director of the Oxford Clinical Trials Research Unit.
Irene Mary Carmel Tracey is Vice-Chancellor of the University of Oxford and former Warden of Merton College, Oxford. She is also Professor of Anaesthetic Neuroscience in the Nuffield Department of Clinical Neurosciences and formerly Pro-Vice-Chancellor at the University of Oxford. She is a co-founder of the Oxford Centre for Functional Magnetic Resonance Imaging of the Brain (FMRIB), now the Wellcome Centre for Integrative Neuroimaging. Her team’s research is focused on the neuroscience of pain, specifically pain perception and analgesia as well as how anaesthetics produce altered states of consciousness. Her team uses multidisciplinary approaches including neuroimaging.
Trudie Lang is a Professor of Global Health Research at the University of Oxford. She specialises in clinical trials research capacity building in low-resource setting, and helped to organise the trial for the drug brincidofovir during the 2014 Ebola virus outbreak.
Sir Peter William Horby is a British physician, epidemiologist, Moh Family Foundation Professor of Emerging Infections and Global Health, and Director of the Pandemic Sciences Institute at the University of Oxford. He is the founder, and former director of the Oxford University Clinical Research Unit in Hanoi, Vietnam which was founded in 2006. In 2014, Horby established the Epidemic Research Group Oxford (ERGO). ERGO incorporates a number of international projects such as the European Commission funded PREPARE, the African coaLition for Epidemic Research, Response and Training (ALERRT), and the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC). Since 2016, Horby has been chair and executive director of ISARIC.
Carl James Heneghan is a British general practitioner physician, a clinical epidemiologist and a Fellow of Kellogg College. He is the director of the University of Oxford's Centre for Evidence-Based Medicine and former Editor-in-Chief of BMJ Evidence-Based Medicine.
Sir Martin Jonathan Landray is a British physician, epidemiologist and data scientist who serves as a Professor of Medicine & Epidemiology at the University of Oxford. Landray designs, conducts and analyses large-scale randomised control trials; including practice-changing international trials that have recruited over 100,000 individuals. Landray previously led the health informatics team that enabled the collection and management of data for the UK Biobank on over half a million people.
Kevin Marsh is a British Malariologist, academic and a researcher. He is a professor of Tropical Medicine and Director of Africa Oxford Initiative at University of Oxford. He is also a senior advisor at African Academy of Sciences.